Dependence of sales on the automated DNA extraction system
First written in FY2016. 14 of 25 entries say "Mitigated", first in FY2017. Latest entry: FY2026.
Precision System Science moved to the "Worse" side of this theme in 2018, 5 years before the typical company in this theme (2023).
The whole theme swung hardest in 2024: 13 of 48 companies on the "Worse" side.
23 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「Net sales for the consolidated fiscal year were ¥2,231 million, up 9.9% year on year.」
Equipment sales were ¥2,231 million, accounting for approximately 42.8% of consolidated sales of ¥5,216 million, down from approximately 47.8% for FY2025. Dependence on equipment sales in the sales mix declined slightly. - FY2026-H1MitigatedAnnual report
「Equipment 1,165 46.0 16.3」「Reagents and consumables 1,001 39.5 52.9」
In the sales mix for the interim consolidated accounting period, equipment accounted for 46.0%, a slight decline from approximately 47.8% for FY2025. Reagents and consumables accounted for 39.5%, up 52.9% year on year. However, this reflected a change in the sales mix categories. - FY2025WorsenedAnnual report
「Equipment 2,244,804 20.0」「Net sales 4,692,629 17.9」
Equipment sales were ¥2,244 million, accounting for approximately 47.8% of consolidated sales. Dependence on equipment sales in the sales mix increased from approximately 47.0% in the previous fiscal year. - FY2025-H1WorsenedAnnual report
「Laboratory automation systems 214 9.8」「Clinical diagnostic systems 900 41.0」
Following the reclassification of equipment sales, laboratory automation systems and clinical diagnostic systems together accounted for 50.8%. This exceeded the approximately 47.0% dependence on equipment sales for FY2024, indicating increased dependence on equipment sales in the sales mix. However, this reflected a change from the previous presentation of equipment as a single category. - FY2024WorsenedAnnual report
「Equipment 1,870,364 △3.7」「Reagents and consumables 1,430,443 △41.4」
Equipment sales were ¥1,870 million, accounting for approximately 47.0% of consolidated sales of ¥3,980 million. Dependence on equipment sales increased from 36.8% for FY2023 as sales of reagents and consumables declined. - FY2024-Q3WorsenedAnnual report
「Equipment 1,360 46.3 △12.0」「Reagents and consumables 1,077 36.6 △45.5」
Equipment accounted for 46.3% of the cumulative sales mix for the first three quarters, while reagents and consumables accounted for 36.6%. Dependence on equipment sales rose further from 36.8% for FY2023 and 45.3% for FY2024-Q2. - FY2024-Q2WorsenedAnnual report
「Equipment 911 45.3 △28.1」「Reagents and consumables 743 36.9 △48.1」
Equipment accounted for 45.3% of the cumulative sales mix for the first two quarters, exceeding both 36.8% for FY2023 and 44.9% for FY2024-Q1. Meanwhile, the ratio of reagents and consumables declined to 36.9%, increasing dependence on equipment sales in the sales mix. - FY2024-Q1WorsenedAnnual report
「Equipment 481 44.9 △15.4」「Reagents and consumables 428 39.9 △44.4」
Equipment accounted for 44.9% of the first-quarter sales mix, up from 36.8% for FY2023. The ratio of reagents and consumables declined to 39.9%, increasing dependence on equipment sales in the sales mix. - FY2023MitigatedAnnual report
「Equipment, including DNA/RNA (nucleic acid) extraction systems and fully automated PCR testing systems, accounted for 36.8% of the Group's sales mix for the fiscal year ended June 2023, indicating a high level of dependence on equipment sales.」
Dependence on equipment sales declined from 40.9% in the previous fiscal year to 36.8%. However, it remained high, and the policy of shifting the business toward a focus on reagents and consumables continued. - FY2023-Q2MitigatedAnnual report
「Equipment 1,268 40.6 △13.3」「Reagents and consumables 1,432 45.9 △12.2」
In the cumulative sales mix for the first two quarters, equipment accounted for 40.6%, below the previous fiscal year's full-year figure of 40.9%. Dependence on equipment sales in the sales mix declined slightly. - FY2023-Q1Equipment ratio up year on year but below the full-year figure for the previous fiscal yearAnnual report
「Equipment 569 37.3 △15.1」「Reagents and consumables 770 50.5 △21.7」
In the first-quarter sales mix, equipment accounted for 37.3% and reagents and consumables for 50.5%. The equipment ratio increased from 35.8% in the same quarter of the previous fiscal year, but remained below the previous fiscal year's full-year figure of 40.9%. - FY2022MitigatedAnnual report
「Equipment, including DNA extraction systems and fully automated PCR testing systems, accounted for 40.9% of the Group's sales mix for the fiscal year ended June 2022, indicating a high level of dependence on equipment sales.」
Dependence on equipment sales declined from 46.6% in the previous fiscal year to 40.9%. However, it was still described as remaining at a high level. - FY2022-Q3MitigatedAnnual report
「Equipment 2,212 40.5 △36.6」「Reagents and consumables 2,563 46.9 △6.9」
In the cumulative sales mix for the first three quarters, equipment accounted for 40.5% and reagents and consumables for 46.9%. The equipment ratio declined from 40.7% in the previous cumulative period, and concentration in equipment sales decreased slightly. - FY2022-Q2WorsenedAnnual report
「Equipment 1,462 40.7 △38.5」「Reagents and consumables 1,631 45.4 △8.2」
In the cumulative sales mix for the first two quarters, equipment accounted for 40.7% and reagents and consumables for 45.4%. The equipment ratio increased from 35.8% in the immediately preceding first quarter. - FY2022-Q1MitigatedAnnual report
「Equipment 670 35.8 △40.3」「Reagents and consumables 983 52.5 28.9」
By product category, equipment accounted for 35.8% of sales in the first quarter, while reagents and consumables accounted for 52.5%, indicating lower concentration in equipment sales than in the first quarter of the previous fiscal year. - FY2022-Q1MitigatedAnnual report
「Equipment 670 35.8 △40.3」「Reagents and consumables 983 52.5 28.9」
In the sales mix for the first quarter, equipment accounted for 35.8%, down, while reagents and consumables accounted for 52.5%. The sales mix was less dependent on equipment sales than in the first quarter of the previous fiscal year. - FY2021MitigatedAnnual report
「Equipment sales, including DNA extraction systems and fully automated PCR testing systems, accounted for a high 46.6% of the group’s revenue mix for the fiscal year ended June 2021.」
Dependence on equipment sales decreased from 58.2% in the previous fiscal year to 46.6%. Although the Company has stated its intention to shift its business focus toward reagents and consumables, dependence remained high. - FY2020MitigatedAnnual report
「The group’s dependence on this system was high, accounting for 58.2% of group revenue for the fiscal year ended June 2020.」
Revenue dependence on automated DNA extraction systems and other equipment decreased from 61.5% in the previous fiscal year to 58.2%. However, it remained high, and the policy of reducing dependence through new product lines, including in the clinical diagnostics field, remains in place. - FY2019WorsenedAnnual report
「The group’s dependence on this system was high, accounting for 61.5% of group revenue for the fiscal year ended June 2019.」
Revenue dependence on automated DNA extraction systems and other equipment increased from 52.3% in the previous fiscal year to 61.5%. - FY2018WorsenedAnnual report
「The group’s dependence on this system was high, accounting for 52.3% of group revenue for the fiscal year ended June 2018.」
Revenue dependence on automated DNA extraction systems and other equipment increased from 33.6% in the previous fiscal year to 52.3%. The policy of reducing dependence through new product lines remains in place. - FY2017MitigatedAnnual report
「The group’s dependence on this system was high, accounting for 33.6% of group revenue for the fiscal year ended June 2017.」
Revenue dependence on automated DNA extraction systems was 33.6%, down from 53.4% in the previous fiscal year. The Company also stated its policy of reducing this dependence through new product lines and expansion in the clinical diagnostics field. - FY2016First statedAnnual report
「The group’s dependence on this system was high, accounting for 53.4% of group revenue for the fiscal year ended June 2016. Accordingly, the group’s results are expected to be affected by changes in user demand for the system and competition between the system and products offered by other companies.」
Revenue dependence on automated DNA extraction systems was quantified at 53.4%, with changes in demand and competitive pressures identified as risks.